Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 4:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 543 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Cyclosporins Clear all
Recruiting Phase 2 Interventional Results available

Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)

NCT04304820
View directory record Official record
Conditions
Severe Aplastic Anemia
Interventions
Eltrombopag, Cyclosporine, Horse-Anti-thymocyte-Globulin
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
3 Years to 99 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2033
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 19, 2026, 4:21 PM EDT
Completed Not applicable Interventional

Low Dose Cyclosporin and Methotrexate Therapy in Diabetes

NCT00905073
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
cyclosporin and methotrexate
Drug
Lead sponsor
Georgetown University
Other
Eligibility
8 Years to 18 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1990 – 1994
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 13, 2011 · Synced Oct 19, 2026, 4:21 PM EDT
Completed Phase 2 Interventional Results available

Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma

NCT00345865
View directory record Official record
Conditions
Lymphoma
Interventions
carmustine, cyclophosphamide, etoposide, peripheral blood stem cell transplantation, irradiation therapy, G-CSF, Cytarabine
Drug · Procedure · Radiation + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 75 Years
Enrollment
473 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Oct 19, 2026, 4:21 PM EDT
Completed Phase 4 Interventional

Tacrolimus/Sirolimus Versus Tacrolimus/Mycophenolate Mofetil (MMF) Versus Neoral/Sirolimus in Adult, Primary Kidney Transplantation

NCT00681213
View directory record Official record
Conditions
Adult Primary Kidney Transplantation
Interventions
Tacrolimus/Sirolimus, Tacrolimus/MMF, Neoral/Sirolimus
Drug
Lead sponsor
University of Miami
Other
Eligibility
16 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 22, 2023 · Synced Oct 19, 2026, 4:21 PM EDT
Completed Phase 2 Interventional Results available

A Study of BMS-224818 (Belatacept) in Patients Who Have Undergone a Kidney Transplant and Are Currently on Stable Cyclosporine or Tacrolimus Regimen With or Without Corticosteroids

NCT00402168
View directory record Official record
Conditions
Renal Transplant
Interventions
Belatacept, Cyclosporine A, Tacrolimus
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
9
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2017 · Synced Oct 19, 2026, 4:21 PM EDT
Completed Not applicable Interventional Results available

A Phase 2 Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft Versus Host Disease

NCT00350545
View directory record Official record
Conditions
Graft vs Host Disease
Interventions
Rituximab, Prednisone, Cyclosporine A, tacrolimus
Drug
Lead sponsor
Stanford University
Other
Eligibility
1 Year to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Oct 19, 2026, 4:21 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Lenalidomide in Combination With Cyclosporine A in Patients With Myelodysplastic Syndromes

NCT00840827
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
lenalidomide, cyclosporine A
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Oct 19, 2026, 4:21 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Sirolimus (Rapamune ) for Relapse Prevention in People With Severe Aplastic Anemia Responsive to Immunosuppressive Therapy

NCT02979873
View directory record Official record
Conditions
Severe Aplastic Anemia
Interventions
Sirolimus
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 99 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 19, 2026, 4:21 PM EDT
Not yet recruiting Phase 4 Interventional

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

NCT07352566
View directory record Official record
Conditions
Psoriasis, Atopic Dermatitis
Interventions
In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil, Calcipotriene, Tapinarof, Crisaborole, Tacrolimus, Adalimumab, Etanercept, Certolizumab, Infliximab, Secukinumab, Ixekizumab, Apremilast, Risankizumab, Ustekinumab, Hydroxychloroquine, Methotrexate, Mycophenolate, Azathioprine, Chloroquine, Cyclosporine, Tofacitinib, Deucravacitinib, Dupilumab, Tralokinumab, Guselkumab, Tildrakizumab, Baractinib, Abrocitinib, Upadacitinib, Lebrikizumab, Nemolizumab, Ruxolitinib, Bimekizumab, Roflumilast
Device · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 19, 2026, 4:21 PM EDT
Terminated Phase 2 Interventional Results available

An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients

NCT01467505
View directory record Official record
Conditions
Hepatitis C
Interventions
Telaprevir, Ribavirin, Pegylated Interferon Alfa-2a, Immunosuppressant Regimen
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
20
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2015 · Synced Oct 19, 2026, 4:21 PM EDT
Completed Phase 3 Interventional

S9920 Busulfan Compared With Cyclophosphamide in Patients Undergoing Total-Body Irradiation Plus Peripheral Stem Cell Transplantation for Advanced Myelodysplastic Syndrome or Related Acute Myeloid Leukemia

NCT00005866
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
busulfan, cyclophosphamide, cyclosporine, methotrexate, allogeneic bone marrow transplantation, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
16 Years to 55 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
65
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 38 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 19, 2026, 4:21 PM EDT
Completed Phase 2 Interventional Results available

Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant

NCT01251575
View directory record Official record
Conditions
Adult Acute Lymphoblastic Leukemia, Adult Acute Myeloid Leukemia, Adult Diffuse Large B-Cell Lymphoma, Adult Myelodysplastic Syndrome, Adult Non-Hodgkin Lymphoma, Aggressive Non-Hodgkin Lymphoma, Childhood Acute Lymphoblastic Leukemia, Childhood Acute Myeloid Leukemia, Childhood Diffuse Large B-Cell Lymphoma, Childhood Myelodysplastic Syndrome, Childhood Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia in Remission, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid Cell Neoplasm, Mantle Cell Lymphoma, Plasma Cell Myeloma, Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, T-Cell Prolymphocytic Leukemia, Waldenstrom Macroglobulinemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Hodgkin Lymphoma
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Sirolimus, Total-Body Irradiation
Procedure · Drug · Other + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
4
States / cities
Denver, Colorado • Salt Lake City, Utah • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Oct 19, 2026, 4:21 PM EDT
Completed Phase 2 Interventional Results available

A Myeloablative Conditioning Regimen and Total Body Irradiation Followed by the Transplantation for Patients With Hematological Malignancy

NCT00597519
View directory record Official record
Conditions
Cancer, Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma
Interventions
Fludarabine, Cyclophosphamide, Transplantation
Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
4 Years to 50 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 12, 2016 · Synced Oct 19, 2026, 4:21 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant

NCT00303667
View directory record Official record
Conditions
Acute Myelogenous Leukemia
Interventions
aldesleukin, natural killer cells, cyclophosphamide, fludarabine phosphate, allogeneic hematopoietic stem cell transplantation, total body irradiation, Thymoglobulin, Cyclosporin A
Biological · Drug · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 19, 2026, 4:21 PM EDT
Terminated Phase 1 Interventional

Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases

NCT00376519
View directory record Official record
Conditions
Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Secondary Myelofibrosis
Interventions
cyclophosphamide, cyclosporine, fludarabine phosphate, mycophenolate mofetil, Treg cell infusion, umbilical cord blood transplantation, total-body irradiation
Drug · Procedure · Radiation
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 45 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 2, 2017 · Synced Oct 19, 2026, 4:21 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders

NCT00533923
View directory record Official record
Conditions
AML, ALL, CLL, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Multiple Myeloma, Aplastic Anemia, Myeloproliferative Disorder
Interventions
Cyclophosphamide; Fludarabine; Cyclosporin; CAMPATH-1H (Alemtuzumab); GM-CSF
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
Up to 65 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 18, 2016 · Synced Oct 19, 2026, 4:21 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Reduced-Intensity Conditioning Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma

NCT00054353
View directory record Official record
Conditions
Refractory Multiple Myeloma
Interventions
fludarabine phosphate, melphalan, total-body irradiation, mycophenolate mofetil, cyclosporine, nonmyeloablative allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, laboratory biomarker analysis
Drug · Radiation · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Oct 19, 2026, 4:21 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications

NCT04877288
View directory record Official record
Conditions
Renal Allograft Recipients
Interventions
Belatacept, Tacrolimus, Cyclosporine A, Mycophenolate Mofetil, Enteric Coated Mycophenolate Sodium, Corticosteroids
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years to 17 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2034
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 19, 2026, 4:21 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

NCT04195633
View directory record Official record
Conditions
Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Adult Diffuse Large Cell Lymphoma, Anaplastic Large Cell Lymphoma, Burkitt Lymphoma, Chronic Myeloid Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Hodgkin Lymphoma, Lymphoblastic Lymphoma, Lymphoplasmacytic Lymphoma, Mantle Cell Lymphoma, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome, Prolymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Follicular Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Small Lymphocytic Lymphoma
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine, Filgrastim, Fludarabine, Mycophenolate Mofetil, Mycophenolate Sodium, Total-Body Irradiation, Treosulfan, Bone Marrow Aspiration, Bone Marrow Biopsy, Echocardiography Test, Biospecimen Collection, Computed Tomography, Positron Emission Tomography
Procedure · Drug · Biological + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
6 Months and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 19, 2026, 4:21 PM EDT
Terminated Phase 2 Interventional Results available

Pilot Study of a Homeopathic Therapy in Combination With Cyclosporin (Restasis) in the Treatment of Dry Eye Disease

NCT01072526
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Euphrasia-based homeopathic therapy, Cyclosporin solution
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
21 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 19, 2026, 4:21 PM EDT
Terminated Phase 3 Interventional

Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation

NCT00003056
View directory record Official record
Conditions
Leukemia, Lymphoma, Graft Versus Host Disease
Interventions
cyclosporine, cyclosporine and methotrexate
Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2003
U.S. locations
12
States / cities
Los Angeles, California • Jacksonville, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Oct 19, 2026, 4:21 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation

NCT03842696
View directory record Official record
Conditions
Hematologic Diseases, Acute Leukemia in Remission, Chronic Myelogenous Leukemia - Chronic Phase, Chronic Myelogenous Leukemia, Accelerated Phase, Chronic Myelogenous Leukemia, Blastic Phase, Myelodysplastic Syndromes, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Non Hodgkin Lymphoma, Graft Vs Host Disease, Graft-versus-host-disease
Interventions
Vorinostat, Blood and Marrow Transplant (BMT), Tacrolimus (or cyclosporine), Methotrexate, Mycophenolate Mofetil (MMF), Cyclophosphamide
Drug · Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
3 Years to 39 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
7
States / cities
Aurora, Colorado • Atlanta, Georgia • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 19, 2026, 4:21 PM EDT
Completed Phase 4 Interventional

Bromfenac 0.09% vs Ketorolac 0.4% for Cyclosporine Induction Phase

NCT00520260
View directory record Official record
Conditions
Dry Eye Disease, Ocular Comfort
Interventions
bromfenac, ketorolac
Drug
Lead sponsor
Florida Eye Microsurgical Institute
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Boynton Beach, Florida
Source: ClinicalTrials.gov public record
Updated Feb 19, 2009 · Synced Oct 19, 2026, 4:21 PM EDT
Completed Phase 1 Interventional

Bone Marrow Transplant With Abatacept for Non-Malignant Diseases

NCT01917708
View directory record Official record
Conditions
Hurler Syndrome, Fanconi Anemia, Glanzmann Thrombasthenia, Wiskott-Aldrich Syndrome, Chronic Granulomatous Disease, Severe Congenital Neutropenia, Leukocyte Adhesion Deficiency, Shwachman-Diamond Syndrome, Diamond-Blackfan Anemia, Dyskeratosis-congenita, Chediak-Higashi Syndrome, Severe Aplastic Anemia, Thalassemia Major, Hemophagocytic Lymphohistiocytosis, Sickle Cell Disease
Interventions
Abatacept
Drug
Lead sponsor
Emory University
Other
Eligibility
Up to 21 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Oct 19, 2026, 4:21 PM EDT